

Media release

Ypsomed launches YpsoLoop as the first autoinjector platform designed for circularity

Burgdorf, 21.10.2025, 7 a.m. – Ypsomed launches YpsoLoop, the first autoinjector platform designed for circularity. The two new 1 ml and 2 ml platform versions enable material recovery through a design enabling automated disassembly and efficient recycling, while offering the convenience of a pre-filled, two-step autoinjector. YpsoLoop integrates into existing production environments, supporting a transition toward more sustainable drug delivery solutions.

“With YpsoLoop, we are taking an important step toward a more circular approach in healthcare,” says Ulrike Bauer, Chief Business Officer at Ypsomed. “Achieving circularity requires collaboration across the entire value chain – from device manufacturers and pharma partners to patients. This platform provides the basis for sustainable self-injection solutions that combine usability, safety, and environmental responsibility.”

Designed for circularity

YpsoLoop has been developed following eco-design principles and with circularity in mind. Both the device structure and material selection enable automated disassembly, laying the groundwork for used autoinjector materials to be separated, recovered, and reintroduced into the material cycle rather than discarded as waste. The platform consists of two mono-material subassemblies – one for the syringe unit and one for the drive unit – allowing efficient recycling. By using bio-based and sustainable materials, YpsoLoop achieves an estimated 87 % reduction in material-related CO₂ emissions compared with conventional autoinjectors.

Building on this foundation, Ypsomed is working with its partners to bring circularity into practice throughout the product lifecycle. The company focuses on three priorities: supporting pharmaceutical partners in preparing for implementation, ensuring access to suitable return and recycling systems, and building the disassembly technology required for circular processes.

Supporting patient confidence

Building on Ypsomed’s long-standing experience in self-injection systems, YpsoLoop is designed to ensure safe, comfortable, and reliable use. Its ClickGuide technology provides continuous acoustic feedback throughout the injection process, helping users maintain the recommended holding time and reducing the risk of early lift-offs, as demonstrated in internal usability studies. The ergonomically shaped cap facilitates easy removal, particularly for users with limited dexterity. These features are intended to strengthen confidence in self-administration and support consistent dosing and adherence across diverse patient groups.

Engineered for supply chain integration

The YpsoLoop platform integrates into existing fill/finish and assembly setups, including those used for YpsoMate. This allows pharmaceutical companies and contract manufacturers to adopt the new platform with only minor modifications. YpsoLoop supports industry-standard primary containers and enables straightforward scale-up for global production. This approach protects existing investments while helping partners meet growing market expectations and regulatory requirements for environmental performance and waste reduction.

Contact

Susanne Koehler, Head of Public Relations, Ypsomed Holding AG
+41 34 424 47 32, susanne.koehler@ypsomed.com

Ypsomed Group

Ypsomed is the leading developer and manufacturer of injection systems for the self-administration of liquid medication. As the reliable partner of pharmaceutical and biotech companies for more than 40 years, Ypsomed provides tailored selfcare solutions to meet specific needs. Backed by a proven track record, Ypsomed offers the most comprehensive and innovative platform portfolio for pens, autoinjectors, and on-body devices. Delivered with best-in-class execution and ready to integrate with digital health services, these solutions help simplify therapy and improve the quality of life for millions of people living with chronic conditions. Ypsomed is headquartered in Burgdorf, Switzerland, and operates a global network of manufacturing facilities. More than 2,000 employees worldwide are committed every day to making selfcare simpler and easier.

Ypsomed Holding AG

Brunnmattstrasse 6
3401 Burgdorf
www.ypsomed.com